In a previous article, I made the case that little has changed within the antipsychotic drug landscape over the past 70 years since the only effective medications for the treatment of schizophrenia ...

With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...

Editor’s note Mathematician John Nash, known as the real-life figure portrayed in the Academy Award-winning film ‘A Beautiful ...

In the study, "Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial," published in JAMA Psychiatry, researchers ...

Motivista is a prescription digital therapeutic indicated for the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, ...

Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...

A common question from patients with a new diagnosis of schizophrenia who have responded to initial treatment with antipsychotic medications is whether they must continue taking them for the rest of ...

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Compared with placebo, using antipsychotic drugs for maintenance therapy in patients with schizophrenia is associated ...

The FDA has given Motivista, a prescription digital therapeutic for adults with negative symptoms of schizophrenia, 510(k) ...

The genetic mechanisms underlying heterogeneity in symptom presentation and antipsychotic response in schizophrenia remain unclear, limiting the development of personalized treatment. We integrated ...